1. Inicio
  2. Publicaciones
  3. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Chicharro P.
  • Llamas-Velasco M.
  • Armesto S.
  • Herrera Acosta E.
  • Vidal D.
  • Vilarrasa E.
  • Rivera-Diaz R.
  • De-la-Cueva P.
  • Martorell-Calatayud A.
  • Ballescà F.
  • Belinchon I.
  • Carretero G.
  • Rodriguez L.
  • Romero-Maté A.
  • Pujol-Montcusí J.
  • Salgado L.
  • Coto-Segura P.
  • Baniandrés Rodríguez O.
  • Feltes R.
  • Riera-Monroig J.
  • Dauden E.

Grupos

Abstract

The aim of the study was to assess the long-term effectiveness and safety of secukinumab in Spanish patients with moderate-to-severe psoriasis in a daily practice setting. Nationwide multicenter, observational, retrospective, non-interventional, single-cohort study including patients who initiated treatment with secukinumab in daily clinical practice conditions. Subjects were followed for a minimum of 3 months and a maximum of 24 months. Psoriasis Area Severity Index (PASI), Body Surface Area and Physician's Global Assessments were collected at baseline and months 3, 6, 12, 18 and 24 during treatment. Adverse events and reasons for secukinumab withdrawal were collected and classified for analyses. A total of 384 patients were enrolled in the study. Median PASI declined rapidly from 14.3 at baseline to 2.7 at month 3, 2.1 at month 12, and remained low (2.8) at month 24. Within the group of patients with PASI =10 at baseline (n = 278), 58.3%, 60.4% and 56.5% achieved a PASI90 response at months 3, 12 and 24, respectively. As for absolute PASI, 86.5%, 69.5%, 42.7% and 37% achieved PASI <5, < 3, < 1 and 0, respectively, at month 3. Secukinumab was more effective in biologic-naïve patients and in those with lower Body Mass Index. Secukinumab presented a good long-term safety profile. Secukinumab was effective and safe in a routine clinical setting, in a large cohort of patients with moderate-to-severe plaque psoriasis, in the short-, medium- and long-term (up to 24 months). © 2022 Wiley Periodicals LLC.

Datos de la publicación

ISSN/ISSNe:
1396-0296, 1529-8019

Dermatologic Therapy  WILEY

Tipo:
Article
Páginas:
-
PubMed:
36223184
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,598 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Antibodies, Monoclonal; Cohort Studies; Humans; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; biological product; secukinumab; monoclonal antibody; secukinumab; acute heart infarction; adult; Article; body mass; body surface; candidiasis; clinical practice; cohort analysis; comparative effectiveness; conjunctivitis; controlled study; disease severity; drug efficacy; drug safety; drug withdrawal; female; fracture; human; injection site reaction; laryngitis; long term care; Ludwig angina; major clinical study; male; middle aged; multiple cycle treatment; observational study; patient decision making; Psoriasis Area and Severity Index; psoriasis vulgaris; retrospective study; rhinopharyngitis; septicemia; Spaniard; stomach ulcer; treatment withdrawal; clinical trial; multicenter study; psoriasis; severity of illness index; treatment outcome

Compartir